Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.

Criscitiello, C., Bagnardi, V., Esposito, A., Gelao, L., Santillo, B., Viale, G., et al. (2016). Impact of autoimmune diseases on outcome of patients with early breast cancer. ONCOTARGET, 7(32), 51184-51192 [10.18632/oncotarget.9966].

Impact of autoimmune diseases on outcome of patients with early breast cancer

BAGNARDI, VINCENZO
Secondo
;
2016

Abstract

Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.
Articolo in rivista - Articolo scientifico
Autoimmunity; Clinical outcome; Early breast cancer; Endocrine therapy; Immunology;
Autoimmunity; Clinical outcome; Early breast cancer; Endocrine therapy; Immunology; Oncology
English
51184
51192
9
Criscitiello, C., Bagnardi, V., Esposito, A., Gelao, L., Santillo, B., Viale, G., et al. (2016). Impact of autoimmune diseases on outcome of patients with early breast cancer. ONCOTARGET, 7(32), 51184-51192 [10.18632/oncotarget.9966].
Criscitiello, C; Bagnardi, V; Esposito, A; Gelao, L; Santillo, B; Viale, G; Rotmensz, N; Goldhirsch, A; Curigliano, G
File in questo prodotto:
File Dimensione Formato  
10281-136288.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 4.32 MB
Formato Adobe PDF
4.32 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/136288
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
Social impact